trending Market Intelligence /marketintelligence/en/news-insights/trending/y4T0izhVUv0UOuMni1Ozew2 content esgSubNav
In This List

Bionomics to sell 2 French subsidiaries to Domain Therapeutics

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Bionomics to sell 2 French subsidiaries to Domain Therapeutics

Thebarton, Australia-based Bionomics Ltd. agreed to sell its two French subsidiaries to Domain Therapeutics SA for about €1.8 million.

The units being sold in the transaction are Neurofit SAS and PC SAS, which operate as contract research organizations in France.

Bionomics said the purchase price is equivalent to the intercompany debt it owed to Neurofit and PC for the scientific research services conducted on its drug candidates. Following the transaction, Illkirch-Strasbourg, France-based Domain Therapeutics will assume the debt.

The acquisition offer is subject to conditions, including the signing of definitive contractual documentation and regulatory approval.

Completion of the deal is expected to occur Jan. 31, 2020.